Expression of microRNA related to bone remodeling regulation in plasma in patients with acromegaly

Backgraund. MiсroRNA are small regulatory factors that regulate gene expression by post-transcriptional regulation of mRNA, playing an important role in numerous cellular processes including organogenesis, apoptosis, cell proliferation and differentiation. Acromegaly causes bone fragility, but the pathogenetic mechanism is generally unknown.

Aim. To evaluate levels of microRNA related to bone remodeling regulation in plasma samples from patients with acromegaly

Materials and methods. Fasting plasma samples were taken and stored in aliquot at ≤ -80°C from consecutive subjects with clinically evident and biochemically confirmed active acromegaly and healthy volunteers matched by age, sex and body mass index (BMI). miRNeasy Serum/Plasma Kit, TaqMan Advanced miRNA cDNA Synthesis Kit, TaqMan Advanced miRNA Assays were used to assay plasma miRNA expression. Insulin-like growth factor 1 (IGF1) was measured by immunochemiluminescence assay (Liaison).

Results. We enrolled 40 subjects 22 patients suffered from acromegaly and 18 matched healthy controls) matched by sex, age and BMI. The median age of patients with acromegaly was 42 years (Q25;Q75 – 37;43) with no difference among the groups, p=0.205; BMI – 28 (24;32) kg/m2, p=0.253. The median IGF1 in subjects with acromegaly – 622 (514;1000) ng/ml was significantly higher as compared to the control group (p<0.001). Patients with acromegaly had significantly higher expression of microRNA-100-5р (p=0.051), microRNA-550а-5р (p=0.048), microRNA-7b-5р (p=0.005) and microRNA-96-5р (p=0.042) among 27 bone-specific microRNA tested in plasma

Conclusions. This study reveals that several microRNAs, known to regulate bone remodeling can be detected in plasma samples of patients with acromegaly and may be suggested as biomarkers for skeletal involvement in patients with acromegaly.

microRNA, acromegaly, secondary osteoporosis

1. Потешкин Ю., Пронин В.С., Мельниченко Г.А., и др. Влияние избытка гормона роста и ИРФ-1 на костно-суставную систему при акромегалии. //Актуальная эндокринология. – 2015. – №. 10. – С. 2. [Poteshkin Yu, Pronin VS, Mel'nichenko GA, et al. Growth hormone and IGF-1 effects on articular and skeletal system in acromegaly. Aktual'naya endokrinologiya. 2015;(10):2. (In Russ)]

2. Tritos NA, Klibanski A. Effects of Growth Hormone on Bone. 2016;138:193-211. doi: 10.1016/bs.pmbts.2015.10.008.

3. Tamada D, Kitamura T, Onodera T, et al. Rapid decline in bone turnover markers but not bone mineral density in acromegalic patients after transsphenoidal surgery. Endocr J. 2014;61(3):231-237. doi: 10.1507/endocrj.EJ13-0387.

4. Samelson EJ, Hannan MT, Zhang Y, et al. Incidence and Risk Factors for Vertebral Fracture in Women and Men: 25-Year Follow-Up Results From the Population-Based Framingham Study. J Bone Miner Res. 2006;21(8):1207-1214. doi: 10.1359/jbmr.060513.

5. Kaji H, Sugimoto T, Nakaoka D, et al. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf). 2001;55(2):175-181. doi: 10.1046/j.1365-2265.2001.01280.x.

6. Ezzat S, Melmed S, Endres D, et al. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocr Metab. 1993;76(6):1452-1457. doi: 10.1210/jcem.76.6.8501150.

7. Kayath MJ, Vieira JGH. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int. 1997;7(3):226-230. doi: 10.1007/bf01622293.

8. Бровкина О.И., Белая Ж.Е., Гребенникова Т.А., и др. Экспрессия генов, регулирующих остеогенез, в костной ткани пациентов с акромегалией и эндогенным гиперкортицизмом. //Генетика. – 2017. – Т. 53. – № 8. – С. 981-987. [Brovkina OI, Belaya ZhE, Grebennikova TA, et al. Osteogenesis Regulating Genes Expression in Bone Tissue of Patients with Acromegaly and Endogenic Hypercorticism. Genetika. 2017;53(8):981-987 (In Russ)]

9. Grebennikova TA, Belaya ZE, Rozhinskaya LY, et al. Epigenetic Aspects of Osteoporosis. Annals of the Russian academy of medical sciences. 2015;70(5):541. doi: 10.15690/vramn.v70.i5.1440.

10. Дедов И.И., Молитвословова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии // Проблемы Эндокринологии. – 2013. – Т. 59. – №6. – C. 4-18. [Dedov II, Molitvoslovova NN, Rozhinskaia LI, Mel'nichenko GA. Russian association of endocrinologists national practice guidelines (clinical signs, diagnosis, differential diagnosis, treatment). Acromegaly. Problems of Endocrinology. 2013;59(6):4-18. (In Russ.)] doi: 10.14341/probl20135964-18]

11. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nature Reviews Drug Discovery. 2012;11(5):401-419. doi: 10.1038/nrd3705.

12. Semenova EV, Filatov MV. Genetic and epigenetic markers of gliomas. Cell and Tissue Biology. 2013;7(4):303-313. doi: 10.1134/s1990519x13040123.

13. Chen J-F, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2005;38(2):228-233. doi: 10.1038/ng1725.

14. Zhang Y, Xie R-l, Gordon J, et al. Control of Mesenchymal Lineage Progression by MicroRNAs Targeting Skeletal Gene Regulators Trps1 and Runx2. J Biol Chem. 2012;287(26):21926-21935. doi: 10.1074/jbc.M112.340398.

15. Heilmeier U, Hackl M, Skalicky S, et al. Serum miRNA Signatures Are Indicative of Skeletal Fractures in Postmenopausal Women With and Without Type 2 Diabetes and Influence Osteogenic and Adipogenic Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells In Vitro. J Bone Miner Res. 2016;31(12):2173-2192. doi: 10.1002/jbmr.2897.

16. Shi X-M, Chen Q, Liu W, et al. Identification and Characterization of MicroRNAs Controlled by the Osteoblast-Specific Transcription Factor Osterix. PLoS One. 2013;8(3):e58104. doi: 10.1371/journal.pone.0058104.

17. Li Z, Hassan MQ, Volinia S, et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proceedings of the National Academy of Sciences. 2008;105(37):13906-13911. doi: 10.1073/pnas.0804438105.

18. Fu HL, Pan HX, Zhao B, et al. MicroRNA-100 inhibits bone morphogenetic protein-induced osteoblast differentiation by targeting Smad1. Eur Rev Med Pharmacol Sci. 2016;20(18):3911-3919.

19. Yang M, Pan Y, Zhou Y. miR-96 promotes osteogenic differentiation by suppressing HBEGF-EGFR signaling in osteoblastic cells. FEBS Lett. 2014;588(24):4761-4768. doi: 10.1016/j.febslet.2014.11.008.

20. Dou C, Zhang C, Kang F, et al. MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim Biophys Acta. 2014;1839(11):1084-1096. doi: 10.1016/j.bbagrm.2014.08.002.